www.2curex.com
Open in
urlscan Pro
2a02:2350:5:108:8007:4edb:1a49:5997
Public Scan
Submitted URL: http://inditreat.dk/
Effective URL: https://www.2curex.com/
Submission: On October 03 via manual from DK — Scanned from DE
Effective URL: https://www.2curex.com/
Submission: On October 03 via manual from DK — Scanned from DE
Form analysis 1 forms found in the DOM
Name: mc-embedded-subscribe-form — POST https://2curex.us17.list-manage.com/subscribe/post?u=f3cd36233367eb37dffaf958d&id=07b0c7d0b5
<form action="https://2curex.us17.list-manage.com/subscribe/post?u=f3cd36233367eb37dffaf958d&id=07b0c7d0b5" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank" novalidate="">
<div id="mc_embed_signup_scroll">
<!--h2>Subscribe</h2-->
<!--div class="indicates-required">
<span class="asterisk">*</span> indicates required
</div-->
<p class="mc-field-group">
<!--label for="mce-EMAIL">Email Address <span class="asterisk">*</span></label-->
<input type="email" value="" name="EMAIL" class="required email" id="mce-EMAIL" placeholder="Email *">
</p>
<p class="mc-field-group">
<!--label for="mce-FNAME">Name </label-->
<input type="text" value="" name="FNAME" class="" id="mce-FNAME" placeholder="First name">
</p>
<p class="mc-field-group">
<!--label for="mce-MMERGE2">Last Name </label-->
<input type="text" value="" name="MMERGE2" class="" id="mce-MMERGE2" placeholder="Last name">
</p>
<div id="mce-responses" class="clear">
<div class="response" id="mce-error-response" style="display:none"></div>
<div class="response" id="mce-success-response" style="display:none"></div>
</div><!-- real people should not fill this in and expect good things - do not remove this or risk form bot signups-->
<div style="position: absolute; left: -5000px;" aria-hidden="true">
<input type="text" name="b_f3cd36233367eb37dffaf958d_07b0c7d0b5" tabindex="-1" value="">
</div>
<p class="clear">
<input type="submit" value="Subscribe" name="subscribe" id="mc-embedded-subscribe" class="button">
</p>
</div>
</form>Text Content
* About 2cureX
* Upcoming events
* Upcoming events
* Past events
* Partners
* Clinical partners
* Commercial partners
* Grants
* MicroCaT
* IO-Resp
* ADAPT
* ENDORESIST
* Q&A
* Q&A – Product launch
* Q&A – Patient testing
* Q&A – IndiTreat®
* Q&A – Clinical trials
* Q&A – 2cureX general
* News
* IR
* Regulatory
* Flash News
* Contact
Menu Menu
2cureX Menu
* Home
* 2cureX
▼
* About us
* Our management team
* Our board members
* Our clinical advisory board
* IndiTreat®
▼
* About IndiTreat® test
* For oncologists
▼
* IndiTreat ® test effectiveness
* Supported cancer types
* How IndiTreat works
* Test validation and availability
* Clinical programs
* For patients
* IndiTreat test process
* IndiTreat® Library
* Events
▼
* Upcoming events
* Past events
* Investors
▼
* Share Information
* Financial Calendar
* Latest Company News
* Reports
* Presentations
* Ownership Structure
* Corporate Governance
▼
* General Meetings
* Articles of Association
* Certified Adviser
* Share issues
▼
* Warrant Exercise 2021
* Directed Issue 2020
* Rights Issue 2019
* IPO 2017
* IR Contact 2cureX
* Partners
▼
* Clinical partners
* Commercial partners
* Grants
▼
* MicroCaT
* IO-Resp
* ADAPT
* ENDORESIST
* Q&A
▼
* Q&A – Product launch
* Q&A – Patient testing
* Q&A – IndiTreat®
* Q&A – Clinical trials
* Q&A – 2cureX general
* News
▼
* IR
* Regulatory
* Flash News
* Contact
* About IndiTreat® test
* Investors
THE POWER OF PRECISION.
FOR EVERY ONCOLOGIST.
TODAY.
Every cancer patient deserves the right treatment
for their individual form of cancer.
New
Precision Oncology Webinar: Beyond Biomarkers
Tuesday 5th October 2021 | 15:00 (CET) | Online event | Free Registration
Read
Latest News
2cureX has signed a distribution agreement with specialized diagnostic solutions
leader Werfen, to distribute 2cureX products in Spain
Read more
WHEN IS INDITREAT APPROPRIATE? (FOR CLINICIANS)
For over 2 decades, testing cancer treatments on microtumors rather than on the
patient has been on the horizon. With IndiTreat®, 2cureX makes microtumor
testing an operational reality to serve you and your cancer clinic.
IS INDITREAT FOR YOU? (FOR PATIENTS)
IndiTreat CE IVD is available today for identifying effective chemotherapies of
certain forms of colorectal cancer if a biopsy is feasible. Ask your doctor if
it is possible to consider IndiTreat for your cancer.
KEY BENEFITS OF INDITREAT
* Tumor resistance
Predict tumor resistance and sensitivity to cancer drugs
* Right cancer treatment
Select the most appropriate treatment, in accordance with guidelines or
off-label
* Better patient outcome
Improve patient quality of life through in vitro testing of drug efficacy on
the individual patient
Read more
* Help chemo-naïve CRC patients
Identify the most effective treatment in chemo-naïve colorectal cancer
patients
* Help late-stage CRC patients
Identify the most effective treatment in late-stage colorectal cancer
patients
* Functional precision medicine
Complement the genomic characterisation of tumours with functional data on
resistance and sensitivity to drugs
LATEST PRESS AND NEWS
Aug 26
Press Releases Regulatory
2cureX publishes interim report for the second quarter and first half of 2021
Aug 26
Press Releases Regulatory
2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret
2021
Aug 20
Press Releases
New development of the IndiTreat® technology allows prediction of response to
anti-angiogenic drugs in colorectal cancer.
Aug 18
News
Upcoming events in the fall from 2cureX
STAY UPDATED WITH OUR NEWS AND PRESS RELEASES
Get notified on mail, when news or press releases are posted on our website
Receive company data continuously to your inbox.
To subscribe, please read and approve the following terms. Approve
Subscribe
A real email address must be provided.
An email has been sent to confirm your subscription.
Get notified on mail, when news or press releases are posted on our website
URGENT MEDICAL NEED IN COLORECTAL CANCER
CONTACT INFORMATION
2cureX, Fruebjergvej 3,
2100 Copenhagen, Denmark
Phone: +45 22115399
E-mail: info@2cureX.com
* Home
* 2cureX
* About us
* Our management team
* Our board members
* Our clinical advisory board
* IndiTreat®
* About IndiTreat® test
* For oncologists
* IndiTreat ® test effectiveness
* Supported cancer types
* How IndiTreat works
* Test validation and availability
* Clinical programs
* For patients
* IndiTreat test process
* IndiTreat® Library
* Events
* Upcoming events
* Past events
* Investors
* Share Information
* Financial Calendar
* Latest Company News
* Reports
* Presentations
* Ownership Structure
* Corporate Governance
* General Meetings
* Articles of Association
* Certified Adviser
* Share issues
* Warrant Exercise 2021
* Directed Issue 2020
* Rights Issue 2019
* IPO 2017
* IR Contact 2cureX
* Partners
* Clinical partners
* Commercial partners
* Grants
* MicroCaT
* IO-Resp
* ADAPT
* ENDORESIST
* Q&A
* Q&A – Product launch
* Q&A – Patient testing
* Q&A – IndiTreat®
* Q&A – Clinical trials
* Q&A – 2cureX general
* News
* IR
* Regulatory
* Flash News
* Contact
FOLLOW US ON
2cureX - LinkedIn2cureX - Twitter
--------------------------------------------------------------------------------
© 2017-2021 2cureX - All rights reserved.
Privacy Policy | Imprint
plucera webbyrå